Tacrolimus
Small molecule targets BMPR2, IL2 via activation / inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | PROGRAF | — | 1997-04-22 – 2021-07-16 | fda.gov ↗ |
| Label expansion | US (FDA) | ENVARSUS XR | — | 2018-12-19 | fda.gov ↗ |
| Label expansion | US (FDA) | ASTAGRAF XL | — | 2018-11-29 | fda.gov ↗ |
| Approved | EU (EMA) | Protopic | — | 2002-02-27 | europa.eu ↗ |
| Approved | US (FDA) | PROGRAF | — | 1994-04-08 | fda.gov ↗ |
Trials 482 · started per year
Also used as a comparator or background therapy in 650 trials
Evidence & citations 63 cited values
Every value below carries the sentence it was read from. 1,160 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tacrolimus | “Thirty nine patients were assigned, through a randomized design, to receive tacrolimus ointment 0.1% or a mouthwash composed of calcium hydroxide 10%, hyaluronic acid 0,3%,...” NCT04718311 ↗1080“Envarsus®, the once-daily prolonged-release formulation of tacrolimus, offers the same therapeutic efficacy as the conventional twice-daily immediate-release tacrolimus...” PMID 38444519 ↗ Feb 2024 “Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive...” NCT02885610 ↗ “Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the...” NCT03423225 ↗ “The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate,...” NCT03320642 ↗ “Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF...” NCT03657342 ↗ “Adult patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after orthotropic liver transplantation (OLTx) on...” NCT03603548 ↗ “The development of Advagraf (tacrolimus extended release capsules), which is approved for prevention of rejection in kidney transplant recipients, now provides an opportunity...” NCT02426502 ↗ “A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation...” NCT02040584 ↗ “This phase II, single-center, open-label study will evaluate the comparable efficacy of tacrolimus extended release tablets (Envarsus®) to the standard of care (SOC) twice...” NCT03373227 ↗ “Tacrolimus is a drug administered orally available with different formulations: immediate release (Prograf®), prolonged-release (Advagraf®) and an extended-release one named...” NCT04489134 ↗ “comparing pharmacokinetics (PK), safety, and efficacy of once-daily, prolonged-release tacrolimus (PR-T) with twice-daily, immediate-release tacrolimus (IR-T) in adult de novo...” PMID 30098071 ↗ Aug 2018 “Multi Center Randomized Open-label Phase IV Study to Compare the Efficacy and Safety After Conversion to TacroBell SR Capsule or TacroBell Capsule in Renal Transplant Patients...” NCT04224350 ↗ “Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid...” PMID 33816524 ↗ Mar 2021 “Oral calcineurin inhibitors (tacrolimus 0.075 mg/kg/day in two divided doses, or cyclosporine 2-5 mg/kg/day in two divided doses) administered in combination with standard...” NCT07406932 ↗ “Topical corticosteroid (i.e. Fluticasone 0.05% cream) and topical calcineurin inhibitor (tacrolimus 0.1% ointment) for sensitive areas like periorbital regions, flexures and...” NCT04706559 ↗ “Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque...” NCT01889758 ↗ “The most widely used immunosuppressive regimen, in adult kidney transplant recipients, consists of an induction therapy accompanied by maintenance with tacrolimus,...” NCT03672110 ↗ “1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months...” NCT02117596 ↗ “The primary objective of this study is to evaluate the efficacy of 6-month treatment with Advagraf® converted from 12-month treatment with tacrolimus in stable liver transplant...” NCT04763096 ↗ “A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period...” PMID 27340950 ↗ Aug 2016 “This is an open, prospective study to assess the efficacy and safety of Tacrolimus (FK506) combined with MMF in the treatment of class III, IV, V + IV or V + III lupus nephritis.” NCT00298506 ↗ “The study compared the clinical effectiveness of topical Tacrolimus (TAC) in patches or gel with Triamcinolone acetonide (TRI) gel for erosive/atrophic oral lichen planus (OLP)” PMID 36788511 ↗ Feb 2023 “Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation.” NCT03270462 ↗ “A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule” NCT02268201 ↗ “The researcher want to determine whether the combined use of pulsed dye laser (PDL) therapy and topical tacrolimus or pimecrolimus will improve PWS therapeutic outcome.” NCT00969397 ↗ “Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)” NCT01380535 ↗ “A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers.” PMID 25160518 ↗ Sep 2014 “Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)” NCT01950819 ↗ “CNI dose (tacrolimus or cyclosporine) will be adjusted to maintain low tacrolimus or cyclosporine whole blood trough levels from month 3 to month 24 or End of Study” NCT06676696 ↗ “Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.” NCT05471050 ↗ “Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.” NCT04761731 ↗ “A prospective open-label study included 60 stable liver transplant recipients who underwent 1:1 conversion from twice-daily tacrolimus to once-daily tacrolimus.” PMID 32911703 ↗ Sep 2020 “1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by” NCT00555373 ↗ “Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate” NCT01749111 ↗ “The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.” NCT03769298 ↗ “Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough.” NCT01921218 ↗ “Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.” NCT02416674 ↗ “receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.” NCT01137084 ↗ “Prograf and Envarsus are two different formulations of Tacrolimus which is used as an immunosuppressant in liver transplant (LT) patients.” NCT05655273 ↗ “A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.” NCT03644667 ↗ “Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30” NCT04104438 ↗ “Starting on Day -2, you will receive tacrolimus by vein as a continuous (nonstop) infusion until you are able to take it by mouth.” NCT01983761 ↗ “Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days.” NCT00763490 ↗ “Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）” NCT06949267 ↗ “Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3” NCT02105155 ↗ “Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.” NCT00360685 ↗ “Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy.” NCT01889381 ↗ “Tacrolimus 0.1 mg/kg/12h starting as soon as treatment allocation arrives to obtain targeting troughs levels of 8-15 ng/ml” NCT01195194 ↗ “Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.” NCT01459107 ↗ “Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT.” NCT00096460 ↗ “including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.” NCT05247203 ↗ “Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours” NCT04711291 ↗ “Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)” NCT04415476 ↗ “Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation” NCT03689075 ↗ “Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL.” NCT05298358 ↗ “These newer medications include Prograf (tacrolimus), Cellcept (mycophenolate mofetil), and Rapamune (sirolimus).” NCT00352092 ↗ “switching from the current standard of care twice daily Adoport (Tacrolimus) to once daily Envarsus (tacrolimus)” NCT04973982 ↗ “Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)” NCT01020539 ↗ “* Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.” NCT00912223 ↗ “Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose.” NCT03762473 ↗ “immediate-release tacrolimus (IR-Tac) and once-daily extended-release tacrolimus (LifeCycle Pharma Tac [LCPT])” PMID 29162334 ↗ Nov 2017 “prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus” NCT00214279 ↗ “Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present)” NCT03314974 ↗ “Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids.” NCT02561767 ↗ “The standard therapy of twice daily immediate release Tacrolimus will be compared to Envarsus once daily.” NCT03823768 ↗ “ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant” NCT02956005 ↗ “apply topical 0.1% tacrolimus ointment twice daily combined with NB-UVB phototherapy once every other day” NCT07307534 ↗ “Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.” PMID 25613762 ↗ Feb 2015 “* Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL” NCT00849147 ↗ “Tacrolimus ointment 0.1% has shown promising results for treating vitiligo in many prospective studies.” NCT01841008 ↗ “Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis” NCT01203709 ↗ “Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths.” NCT02500212 ↗ “with tacrolimus starting from day +5 and single dose anti-thymoglobin at 2.5mg/kg as GVHD prophylaxis” NCT06705062 ↗ “Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)” NCT03978494 ↗ “LCP-tacrolimus displays enhanced oral bioavailability compared to immediate-release (IR-) tacrolimus.” PMID 37588007 ↗ Aug 2023 “LCP-Tacro is a tablet containing the same active ingredient (tacrolimus) that is in Prograf capsules” NCT00772148 ↗ “Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)” NCT02053545 ↗ “Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients” NCT03461445 ↗ “plus oral Tacrolimus 1.0 mg two times a day titrated to trough Tacrolimus levels between 4-6 ng/ml” NCT05546047 ↗ “Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml” NCT00785330 ↗ “Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper” NCT01565616 ↗ “Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty” NCT00463723 ↗ “Tacrolimus-based immunosuppression is the standard of care following liver transplantation (LT).” NCT05242315 ↗ “Tacrolimus is a well-known immunosuppressiv active substance which is hardly soluble in water.” NCT04532710 ↗ “Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452” NCT03747614 ↗ “Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus” NCT02432833 ↗ “Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus” NCT00972660 ↗ “Tacrolimus is an anti-inflammatory and immunosuppressive macrolide that targets CD4+ cells.” PMID 36762782 ↗ Jan 2023 “Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.” NCT06517641 ↗ “Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)” NCT01751997 ↗ “The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.” NCT02166177 ↗ “LCP-Tacro is an extended-release formulation of tacrolimus designed for once-daily dosing.” PMID 24493215 ↗ Mar 2014 “Tacrolimus (0,2 à 0,3 mg/kg/day per os divided into 2 doses or 0.05 to 0.1 mg/kg/d IVSE)” NCT06646497 ↗ “Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV.” NCT00520130 ↗ “Researchers can choose cyclosporin A or tacrolimus according to patient tolerance.” NCT03192657 ↗ “in combination with tacrolimus and mycophenolate mofetil (MMF) for GVHD prevention” NCT06926595 ↗ “Tacrolimus or cyclosporine: dosed according to trough levels per standard of care” NCT01053221 ↗ “Tacrolimus: 0.02 mg/kg, start day 3. Continue intravenous (IV) or by mouth (PO).” NCT02356159 ↗ “Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.” NCT01208896 ↗ “LCP-Tacro tablets (tacrolimus, Veloxis Pharmaceuticals A/S, Horsholm, Denmark)” NCT01438710 ↗ “standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone” NCT06584773 ↗ “calcineurin inhibitor (tacrolimus or cyclosporine) immunosuppression therapy” NCT01837043 ↗ “Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml” NCT00679042 ↗ “followed by mycophenolate-free tacrolimus-based immunosuppression for 12 mo.” PMID 37525369 ↗ Aug 2023 “Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.” NCT00377962 ↗ “standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)” NCT03913026 ↗ “Tofacitinib 5mg BID+thalidomide 50mg BID+tacrolimus 0.1mg/kg QD per oral” NCT06438679 ↗ “Control group - Tacrolimus twice daily in addition to standard of care.” NCT03438773 ↗ “The study allowed SOC regimen is tacrolimus + sirolimus or everolimus.” NCT06552169 ↗ “Patients will start their GVHD prophylaxis with Tacrolimus on Day -9.” NCT01049854 ↗ “mycophenolate mofetil (MMF) and tacrolimus converted to sirolimus” NCT00619528 ↗ “Twice daily medication regimen (Tacrolimus and mycophenolic acid)” NCT03555448 ↗ “Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml.” NCT01230502 ↗ “tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)” NCT02392780 ↗ “may receive tacrolimus days +5 through +60 instead of sirolimus” NCT03922724 ↗ “Tacrolimus (prograf) is a T-cell specific calcineurin inhibitor” NCT00982072 ↗ “Tacrolimus is the most common immunosuppressive drug used now.” NCT03173820 ↗ “GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3” NCT00745420 ↗ “tacrolimus, extended-release tablets, a calcineurin inhibitor” NCT04665310 ↗ “ENVARSUS XR is a new FDA-approved formulation of tacrolimus.” NCT04838288 ↗ “Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)” NCT01056237 ↗ “Start of tacrolimus \& Start of mycophenolate mofetil (MMF)” NCT03128996 ↗ “tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)” NCT04936282 ↗ “Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID” NCT00983645 ↗ “May be cyclosporine, mycophenolate mofetil, or tacrolimus” NCT00135694 ↗ “Envarsus is a once-a-day oral formulation of tacrolimus.” NCT03005236 ↗ “Cyclosporine A or Tacrolimus 3 mg/kg/day from -1 to 120” NCT05515029 ↗ “FK506 (Tacrolimus) in Pulmonary Arterial Hypertension” NCT01647945 ↗ “• Calcineurin inhibitor (cyclosporine or tacrolimus)” NCT07124078 ↗ “The target serum level for tacrolimus is 5-10 ng/mL.” NCT01106833 ↗ “• Calcineurin inhibitor (cyclosporine or tacrolimus)” NCT06821542 ↗ “in a regimen wih low doses tacrolimus and prednisone” NCT02671318 ↗ “Tacrolimus is the active ingredient in ENVARSUS XR.” NCT03864926 ↗ “Day -3: Begin Tacrolimus or cyclosporine Begin MMF” NCT00920972 ↗ “Tacrolimus levels for 2 years between 8-10 ng/ml.” NCT00798785 ↗ “Tacrolimus initially 1 mg BID; max dose 3 mg BID.” NCT03828019 ↗ “Tacrolimus 0.03 mg/kg IBW Q24H starting on Day 5” NCT04187105 ↗ “tacrolimus (low dose, trough level of 5-12ng/ml)” NCT02095418 ↗ “Tacrolimus Sustained-release Capsules (ADVAGRAF)” NCT01288664 ↗ “Tacrolimus prolonged-release hard capsules (QD)” NCT03216447 ↗ “This group will receive Tacrolimus+Everolimus.” NCT01707849 ↗ “Envarsus XR® & Immediate Release Tacrolimus” NCT03979365 ↗ “FK, Tacrolimus, MMF, Mycophenolate Mofetil” NCT01062555 ↗ “Tacrolimus, Cyclosporin, NeoOral, Prograf” NCT01455649 ↗ “Advagraf® (one daily dose of Tacrolimus)” NCT00930241 ↗ “tacrolimus prolonged release (Advagraf®)” NCT01435291 ↗ “Extended Release Tacrolimus (Advagraf®)” NCT01680952 ↗ “Tacrolimus (target trough 15-25 ng/mL)” NCT07519005 ↗ “tacrolimus po trough levels 3-6 ng/ml” NCT00566813 ↗ “Basiliximab, Tacrolimus, Prednisolone” NCT07572071 ↗ “Tacrolimus with Targeted Nursing Care” NCT07049172 ↗ “Tacrolimus (IV or PO) beginning Day 5” NCT01597778 ↗ “2. Tacrolimus, oral, 2-4mg per day.” NCT05863936 ↗ “topical tacrolimus for face lesions” NCT05706636 ↗ “Immunosuppression: Tacrolimus/MMF” NCT04103879 ↗ “Tacrolimus (objective 5-7 ng/ml)” NCT06254248 ↗ “Modified release tacrolimus” NCT02432053 ↗ “2 TBI; CAMPATH; TACROLIMUS” NCT00578266 ↗ “Prograf (tacrolimus)” NCT01187953 ↗ “Tacrolimus (Prograf)” NCT00252655 ↗ “Tacrolimus (Prograf)” NCT01936519 ↗ “tacrolimus ointment” NCT00106496 ↗ “* Tacrolimus (Tac)” NCT02988466 ↗ “tacrolimus 0.1 %” NCT00762658 ↗ “Tacrolimus” NCT03762473 ↗ “tacrolimus” NCT00132691 ↗ “Tacrolimus” NCT03465410 ↗ “Tacrolimus” NCT01288521 ↗ “Tacrolimus” NCT02339246 ↗ “tacrolimus” NCT05077254 ↗ “Tacrolimus” NCT06178146 ↗ “tacrolimus” NCT00132691 ↗ “Tacrolimus” NCT00355862 ↗ “Tacrolimus” NCT01374750 ↗ |
| Known as | ADOPORT | “Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)” NCT02961608 ↗3“Immediate release Tacrolimus (Prograf/Adoport)” NCT03465410 ↗ “Tacrolimus monohydrate (ADOPORT®)” NCT03076151 ↗ |
| Known as | Advagraf | “Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the...” NCT03423225 ↗32“Adult patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after orthotropic liver transplantation (OLTx) on...” NCT03603548 ↗ “The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day...” NCT04761731 ↗ “A Phase IV, Randomized, Open-label, Comparative, Single-center Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf® (Modified Release Tacrolimus) and Prograf®...” NCT01339468 ↗ “Tacrolimus is a drug administered orally available with different formulations: immediate release (Prograf®), prolonged-release (Advagraf®) and an extended-release one named...” NCT04489134 ↗ “The aim of the conversion is to investigate the effects of the multi-drug resistance (MDR1, gene symbol ABCB1) genotype on the trough blood levels of tacrolimus modified...” NCT03751332 ↗ “Current formulations of tacrolimus, such as Prograf® and Advagraf™, exhibit limitations in terms of pharmacokinetics and tolerability, related in part to suboptimal bioavailability.” PMID 37170284 ↗ May 2023 “A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers” NCT01681134 ↗ “Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3” NCT02105155 ↗ “Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.” NCT01206569 ↗ “Advagraf is a FK506 formulation that has been demonstrated to lower the risk of nonadherence” NCT04237246 ↗ “Tacrolimus Sustained-release Capsules (ADVAGRAF)” NCT01309477 ↗ “Tacrolimus Sustained-release Capsules (ADVAGRAF)” NCT01328834 ↗ “once-daily tacrolimus formulation (Advagraf®)” NCT03216447 ↗ “tacrolimus prolonged release (Advagraf®)” NCT01435291 ↗ “Advagraf® (one daily dose of Tacrolimus)” NCT00930241 ↗ “Extended Release Tacrolimus (Advagraf®)” NCT01680952 ↗ |
| Known as | ADVAGRAF: Tacrolimus Sustained-release Capsules | “ADVAGRAF: Tacrolimus Sustained-release Capsules” NCT01328834 ↗ |
| Known as | Astagraf XL | “Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients” NCT03194321 ↗ |
| Known as | ENVARSUS | “Envarsus®, the once-daily prolonged-release formulation of tacrolimus, offers the same therapeutic efficacy as the conventional twice-daily immediate-release tacrolimus...” PMID 38444519 ↗ Feb 202415“Adult patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after orthotropic liver transplantation (OLTx) on...” NCT03603548 ↗ “The hypothesis of this study is that kidney transplant recipients receiving once-a-day extended release tacrolimus (Envarsus) will have outcomes that are not inferior to those...” NCT03438773 ↗ “Tacrolimus is a drug administered orally available with different formulations: immediate release (Prograf®), prolonged-release (Advagraf®) and an extended-release one named...” NCT04489134 ↗ “Tacrolimus XR (Envarsus) is a once daily formulation with delayed absorption and lower peak levels while maintaining similar trough levels as seen with IR tacrolimus.” NCT04917718 ↗ “Envarsus® is also a prolonged-release once-daily tacrolimus formulation, developed using MeltDose™ drug-delivery technology to increase drug bioavailability” PMID 37170284 ↗ May 2023 “a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients” NCT03797196 ↗ “Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant” NCT03713645 ↗ “Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus” NCT02432833 ↗ “Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]” NCT04496401 ↗ “Patients will be converted to Envarsus formulation of tacrolimus” NCT03461445 ↗ “Once daily medication regimen (Envarsus and azathioprine)” NCT03555448 ↗ “Tacrolimus Extended Release Oral Tablet [Envarsus]” NCT03289650 ↗ “Tacrolimus Extended Release Oral Tablet [Envarsus]” NCT03828682 ↗ |
| Known as | ENVARSUS XR | “This is a randomized, open-label, controlled clinical trial designed to compare clinical outcomes after kidney transplantation using extended-release tacrolimus (Envarsus XR)...” NCT04225988 ↗9“Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation.” NCT03270462 ↗ “using extended release tacrolimus (Envarsus XR, Veloxis), will provide more stable, more effective, and less toxic levels of tacrolimus in renal allograft recipients.” NCT03511560 ↗ “Among once-daily tacrolimus formulations, LCP-tacrolimus (ENVARSUS XR®) is approved for the prevention of transplant rejection in adult liver allograft recipients.” NCT06354179 ↗ “Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours” NCT04711291 ↗ “ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant” NCT02956005 ↗ “LCP-Tacro (Envarsus® XR, Veloxis Pharmaceuticals), a new once-daily formulation of tacrolimus” NCT03289650 ↗ “Envarsus XR (0.13mg/kg/day) will be administered once a day.” NCT04773392 ↗ |
| Known as | ER-TAC | “The aim of this study was to assess the efficacy and safety of low-dose SRL with extended-release tacrolimus (ER-TAC) versus MMF with ER-TAC.” PMID 28810721 ↗ Aug 2017 |
| Known as | FK506 | “A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506
(Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized,
Two-Arm, Three-Period...” PMID 27340950 ↗ Aug 201635“Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI” NCT06490562 ↗ “Tacrolimus, also known as FK506, is an agent mainly used after allogeneic organ transplant to lower risk of organ rejection.” NCT03540472 ↗ “Tacrolimus (FK-506) is a new immunosuppressive agent that acts by inhibiting T-cell activation and cytokine release.” NCT01333410 ↗ “Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL.” NCT05298358 ↗ “Among topical immunosuppressants the most used ones are tacrolimus, also known as FK506 and cyclosporine A (CsA).” NCT01850979 ↗ “Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.” NCT04956484 ↗ “Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.” NCT05929248 ↗ “Tacrolimus, formerly known as FK506, is a macrolide antibiotic possessing immunosuppressive properties.” NCT06203470 ↗ “0.1% tacrolimus (FK-506) ophthalmic ointment with 2% cyclosporine eye drops in the treatment of VKC.” NCT01068054 ↗ “Advagraf is a FK506 formulation that has been demonstrated to lower the risk of nonadherence” NCT04237246 ↗ “CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP” NCT05899907 ↗ “Drug: Tacrolimus（FK506）” NCT03315052 ↗ “tacrolimus (FK506)” NCT00302523 ↗ “Tacrolimus (FK506)” NCT00429377 ↗ “tacrolimus (FK506)” NCT00615173 ↗ “Tacrolimus (FK506)” NCT00965094 ↗ “tacrolimus (FK506)” NCT00615667 ↗ “Tacrolimus（FK506）” NCT02752529 ↗ “FK 506” NCT01168219 ↗ |
| Known as | FK506E | “Other Names: * FK506E * MR4 * tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug:...” NCT01435291 ↗ |
| Known as | FK506MR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00619398 ↗ |
| Known as | Fujimycin | “Fujimycin” NCT02220985 ↗ |
| Known as | Hecoria | “Hecoria” NCT02220985 ↗1“Hecoria” NCT03096782 ↗ |
| Known as | immediate-release tacrolimus | “Immediate-release tacrolimus for at least 3 months after liver transplantation, and then convert to tacrolimus sustained-release capsules at a ratio of 1:1 to 1:1.2; Take the...” NCT06183892 ↗2“Our study compared dosing of LCPT with current standard-of-care tacrolimus [immediate-release tacrolimus (IR-Tac) or prolonged-release tacrolimus (PR-Tac)] during the 6 months...” PMID 36017158 ↗ Mar 2022 “Comparison of Early Conversion to LCP-Tacrolimus (ENVARSUS XR) to Immediate-Release Tacrolimus in Lung Transplant Recipients.” PMID 40294109 ↗ May 2025 |
| Known as | IR tacrolimus | “As soon as the patient is deemed appropriate to take medications via the oral route, they will be converted from IR tacrolimus to Envarsus XR.” NCT04420195 ↗1“intermediate release tacrolimus (IR-tacrolimus, IR-tacro).” NCT04469842 ↗ |
| Known as | IR-Tac | “Our study compared dosing of LCPT with current standard-of-care tacrolimus [immediate-release tacrolimus (IR-Tac) or prolonged-release tacrolimus (PR-Tac)] during the 6 months...” PMID 36017158 ↗ Mar 20222“rather than immediate release tacrolimus (IR-Tac) which is prescribed as a two doses per day (every 12 hours)” NCT04711291 ↗ “immediate-release tacrolimus (IR-Tac)” PMID 29162334 ↗ Nov 2017 |
| Known as | IR-tacro | “intermediate release tacrolimus (IR-tacrolimus, IR-tacro).” NCT04469842 ↗ |
| Known as | IRT | “We conducted a prospective, open-label trial of lung transplant recipients who underwent early conversion (within 30 days) to LCP tacrolimus (LCPT, n = 40) and compared...” PMID 40294109 ↗ May 2025 |
| Known as | LCP-Tac | “This observational retrospective study analyzed the effectiveness and safety of conversion from twice-daily immediate-release tacrolimus (IR-Tac) or once-daily...” PMID 31815310 ↗ Dec 2019 |
| Known as | LCP-Tacro | “LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects...” NCT01438710 ↗10“Tacrolimus is a drug administered orally available with different formulations: immediate release (Prograf®), prolonged-release (Advagraf®) and an extended-release one named...” NCT04489134 ↗ “LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL” NCT00608894 ↗ “Long-acting Tacrolimus (LCP-tacrolimus) may have the potential to bridge the balance of providing potent immunosuppression” NCT04469842 ↗ “maintenance immunotherapy with LCP Tacro™ tablets (tacrolimus, LifeCycle Pharma A/S, Hoersholm, Denmark) once daily” NCT00817206 ↗ “LCP-Tacro is a tablet containing the same active ingredient (tacrolimus) that is in Prograf capsules” NCT00772148 ↗ “ENVARSUS® (LCP Tacro - extended release tacrolimus)” NCT04496401 ↗ “LCP Tacro (tacrolimus)” NCT00496483 ↗ |
| Known as | LCP-tacrolimus | “Among once-daily tacrolimus formulations, LCP-tacrolimus (ENVARSUS XR®) is approved for the prevention of transplant rejection in adult liver allograft recipients.” NCT06354179 ↗3“Comparison of Early Conversion to LCP-Tacrolimus (ENVARSUS XR) to Immediate-Release Tacrolimus in Lung Transplant Recipients.” PMID 40294109 ↗ May 2025 “Long-acting Tacrolimus (LCP-tacrolimus) may have the potential to bridge the balance of providing potent immunosuppression” NCT04469842 ↗ “A new once-daily tacrolimus formulation, LCP-tacrolimus (LCPT), has been developed” PMID 36017158 ↗ Mar 2022 |
| Known as | LCPT | “We conducted a prospective, open-label trial of lung transplant recipients who underwent early conversion
(within 30 days) to LCP tacrolimus (LCPT, n = 40) and compared...” PMID 40294109 ↗ May 20253“The aim of this study was to compare the pharmacokinetic profile, tolerability, and safety of a novel once-daily extended-release formulation of tacrolimus (LCPT) with that of...” PMID 29965950 ↗ Oct 2018 “A new once-daily tacrolimus formulation, LCP-tacrolimus (LCPT), has been developed” PMID 36017158 ↗ Mar 2022 “once-daily extended-release tacrolimus (LifeCycle Pharma Tac [LCPT])” PMID 29162334 ↗ Nov 2017 |
| Known as | LifeCycle Pharma Tac | “once-daily extended-release tacrolimus (LifeCycle Pharma Tac [LCPT])” PMID 29162334 ↗ Nov 2017 |
| Known as | LP-10 | “LP-10, a novel liposomal tacrolimus oral rinse” PMID 41174333 ↗ Oct 2025 |
| Known as | LTac | “everolimus (EVR), low-dose tacrolimus (LTac)” PMID 28141897 ↗ Mar 2017 |
| Known as | LTacrolimus Topical | “Drug: LTacrolimus Topical” NCT04705584 ↗ |
| Known as | MR4 | “Other Names: * FK506E * MR4 * tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug:...” NCT01435291 ↗ |
| Known as | NOV05 | “A Phase 2, Randomized, Double-Masked, Controlled, Proof-of-Concept Study to Evaluate the Safety and Biological Activity of a Water-free Tacrolimus Ophthalmic Solution (NOV05)...” NCT07285070 ↗ |
| Known as | PR-Tac | “Our study compared dosing of LCPT with current standard-of-care tacrolimus [immediate-release tacrolimus (IR-Tac) or prolonged-release tacrolimus (PR-Tac)] during the 6 months...” PMID 36017158 ↗ Mar 2022 |
| Known as | Prograf | “Envarsus®, the once-daily prolonged-release formulation of tacrolimus, offers the same therapeutic efficacy as the conventional twice-daily immediate-release tacrolimus...” PMID 38444519 ↗ Feb 202464“Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus...” NCT06692426 ↗ “Adult patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after orthotropic liver transplantation (OLTx) on...” NCT03603548 ↗ “This phase II, single-center, open-label study will evaluate the comparable efficacy of tacrolimus extended release tablets (Envarsus®) to the standard of care (SOC) twice...” NCT03373227 ↗ “A Phase IV, Randomized, Open-label, Comparative, Single-center Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf® (Modified Release Tacrolimus) and Prograf®...” NCT01339468 ↗ “Tacrolimus is a drug administered orally available with different formulations: immediate release (Prograf®), prolonged-release (Advagraf®) and an extended-release one named...” NCT04489134 ↗ “This is a one year, prospective, randomized, open-label trial examining once versus twice daily tacrolimus dosing regimen using two preparations, extended-release Tacrolimus...” NCT03511560 ↗ “Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque...” NCT01889758 ↗ “Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the...” NCT01438710 ↗ “1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months...” NCT02117596 ↗ “Current formulations of tacrolimus, such as Prograf® and Advagraf™, exhibit limitations in terms of pharmacokinetics and tolerability, related in part to suboptimal bioavailability.” PMID 37170284 ↗ May 2023 “A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers” NCT01681134 ↗ “1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by” NCT00555373 ↗ “The written informed consent to conversion of either tacrolimus (TAC; Prograf®) or cyclosporin A (CSA; Sandimmun Neoral®) to TAC MR4 will be obtained.” NCT03751332 ↗ “A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.” NCT03644667 ↗ “Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3” NCT02105155 ↗ “The main objective of this study is to demonstrate the benefit of the withdrawal of Tacrolimus (Prograf®) on renal function” NCT01292525 ↗ “A first residual blood concentration (C0) of Tacrolimus will be evaluated after 6 administrations of Prograf®, at D10.” NCT00552201 ↗ “Data obtained with tacrolimus prolonged release will be compared with those of tacrolimus immediate release (Prograf®)” NCT01435291 ↗ “These newer medications include Prograf (tacrolimus), Cellcept (mycophenolate mofetil), and Rapamune (sirolimus).” NCT00352092 ↗ “Tacrolimus (Prograf) is a medication that is commonly used in patients who receive a kidney transplant.” NCT00731874 ↗ “It is suspected that Cylosporine A (Sandimmun, TM) is less diabetogenic than Tacrolimus (Prograf, TM).” NCT01268995 ↗ “Tacrolimus administered as Prograf in according to standard protocol at the transplant center” NCT01698541 ↗ “Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)” NCT02961608 ↗ “Tacrolimus (prograf) is a T-cell specific calcineurin inhibitor” NCT00982072 ↗ “interferon beta 1-b (Betaseron®) and tacrolimus (Prograf®)” NCT00298662 ↗ “when compared to immediate-release tacrolimus (Prograf®).” NCT05242315 ↗ “Immediate release Tacrolimus (Prograf/Adoport)” NCT03465410 ↗ “Prograf® (two daily doses of Tacrolimus)” NCT00930241 ↗ “Prograf® (Tacrolimus) OR Cyclosporine” NCT00789308 ↗ “twice-daily tacrolimus (Prograf” NCT02337036 ↗ “Prograf (tacrolimus) capsules” NCT00496483 ↗ “Tacrolimus (Prograf®)” NCT00036153 ↗ “Tacrolimus, Prograf®” NCT00297765 ↗ “tacrolimus (Prograf)” NCT00938860 ↗ “Tacrolimus (Prograf)” NCT00252655 ↗ “Neoral/Prograf” NCT00267189 ↗ “Prograf” NCT02457221 ↗ “Prograf” NCT03096782 ↗ |
| Known as | Prograf (tacrolimus) | “Prograf (tacrolimus)” NCT01492894 ↗ |
| Known as | Prograf capsules (tacrolimus) | “Prograf® capsules (tacrolimus)” NCT00935298 ↗ |
| Known as | Prograf-XL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00720408 ↗ |
| Known as | prolonged-release tacrolimus | “Our study compared dosing of LCPT with current standard-of-care tacrolimus [immediate-release tacrolimus (IR-Tac) or prolonged-release tacrolimus (PR-Tac)] during the 6 months...” PMID 36017158 ↗ Mar 20221“A once-daily administration of prolonged-release tacrolimus has been found to improve patient compliance and offer good efficacy and safety.” NCT06147648 ↗ |
| Known as | Protopic | “Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing calcineurin inhibitor ("Protopic", tacrolimus ointment 0.1%)” NCT04114097 ↗6“Tacrolimus 0.03% ointment (Protopic)” NCT00443105 ↗ “Protopic® (Tacrolimus) 0.1% ointment” NCT03152019 ↗ “Protopic” NCT03096782 ↗ |
| Known as | TAC | “The aim of this study was to compare the long-term safety and efficacy of immunosuppressive regimens consisting of cyclosporine (CsA) plus mycophenolate mofetil (MMF) or...” PMID 19744223 ↗ Sep 200938“In this comparative open-label cohort study, the investigators compared the efficacy and safety of tacrolimus (TAC)and cyclophosphamide (CYC) in the treatment of diffuse...” NCT01207297 ↗ “An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV)...” NCT01927588 ↗ “The efficacy and safety of tacrolimus (TAC) and cyclophosphamide (CTX) were prospectively examined in steroid-dependent or steroid-resistant primary focal segmental...” PMID 23343906 ↗ Jan 2013 “This random, open, control and multicenter clinical trial mainly aims to assess the urine protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous...” NCT03864250 ↗ “The study compared the clinical effectiveness of topical Tacrolimus (TAC) in patches or gel with Triamcinolone acetonide (TRI) gel for erosive/atrophic oral lichen planus (OLP)” PMID 36788511 ↗ Feb 2023 “The calcineurin inhibitors (CNIs) cyclosporine (CsA) and tacrolimus (Tac) are implicated in post-transplant complications such as cardiovascular morbidity.” PMID 23190385 ↗ Nov 2012 “The written informed consent to conversion of either tacrolimus (TAC; Prograf®) or cyclosporin A (CSA; Sandimmun Neoral®) to TAC MR4 will be obtained.” NCT03751332 ↗ “Tacrolimus (TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice.” NCT02891603 ↗ “Tacrolimus (TAC) to ciclosporin A (CSA) conversion studies in stable kidney transplant recipients have reported varying effects on graft function.” PMID 26270340 ↗ Aug 2015 “One year survival of islet cell grafts has been reproducibly achieved under combination immune therapy including tacrolimus (TAC).” PMID 18212631 ↗ Jan 2008 “were randomized to receive everolimus (EVR) + mycophenolic acid (MPA) or were maintained on tacrolimus (TAC) + MPA.” PMID 27648523 ↗ Oct 2016 “The initial target trough levels were 100-200 ng/ml for cyclosporine (CSA) and 4-8 ng/mL for tacrolimus (TAC).” PMID 19670189 ↗ Jun 2009 “concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS)” NCT06365437 ↗ “If CR is not reached, tacrolimus (TAC) or mycophenolate mofetil (MMF) can be used as second-line therapy.” PMID 38233878 ↗ Jan 2024 “Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis” NCT01203709 ↗ “Tacrolimus (TAC) + Mycophenolate mofetil (MMF) + Corticosteroids (CS) up to End of Study (EOS).” NCT03781414 ↗ “Efficacy and safety of protein kinase C inhibitor sotrastaurin (STN) with tacrolimus (TAC)” PMID 25677074 ↗ Feb 2015 “Tacrolimus (Tac)/methotrexate (MTX) is standard graft-versus-host disease (GVHD)” PMID 37352262 ↗ Aug 2023 “Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks.” NCT06147375 ↗ “tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy (IMN)” NCT03549663 ↗ “Tacrolimus (TAC) is effective in treating membranous nephropathy (MN);” PMID 31492152 ↗ Sep 2019 “Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone” NCT00707759 ↗ “treated with both mycophenolate mofetil (MMF) and tacrolimus (Tac)” NCT04207177 ↗ “the most commonly employed 2nd generation CNI tacrolimus (TAC)” NCT04701528 ↗ “mycophenolate mofetil(MMF) combined with tacrolimus(TAC)” NCT05916781 ↗ “continue standard tacrolimus (TAC Control)” PMID 29237235 ↗ Jan 2018 “tacrolimus (Tac), methotrexate (MTX)” NCT06315309 ↗ “Drug: Tacrolimus(TAC)” NCT02137239 ↗ “* Tacrolimus (Tac)” NCT02988466 ↗ “Tacrolimus (TAC)” NCT03663335 ↗ “Tacrolimus (Tac)” NCT02217410 ↗ “Tacrolimus (TAC)” NCT07290777 ↗ “Tacrolimus (Tac)” NCT06615050 ↗ “Tacrolimus (TAC)” NCT00803010 ↗ “tacrolimus (Tac)” PMID 42066960 ↗ Apr 2026 “Tacrolimus (TAC)” NCT01580865 ↗ “Tacrolimus (TAC)” NCT04311632 ↗ “Tacrolimus (Tac)” NCT03674411 ↗ |
| Known as | TAC MR4 | “The written informed consent to conversion of either tacrolimus (TAC; Prograf®) or cyclosporin A (CSA; Sandimmun Neoral®) to TAC MR4 will be obtained.” NCT03751332 ↗ |
| Known as | TacER | “The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety of two different doses of extended-release tacrolimus (TacER) in kidney...” PMID 27862923 ↗ Jan 20171“Tacrolimus extended-release (TAC-ER; Astagraf XL® ) is utilized in many immunosuppressive regimens post-renal transplantation.” PMID 31206808 ↗ Jul 2019 |
| Known as | Tacforius | “Tacforius” NCT03670966 ↗ |
| Known as | Tacni | “Tacrolimus administered as generic formulation Tacni in accordance with standard protocol at the transplant center” NCT01698541 ↗ |
| Known as | Tacro | “We conducted a prospective clinical trial testing nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) ± ipilimumab (IPI) in KTR with advanced cutaneous cancers.” PMID 38252910 ↗ Jan 20243“with planned dose reductions of tacrolimus (Tacro) over the first year postoperatively.” PMID 14742990 ↗ Jan 2004 “Tacrolimus (Tacro™)” NCT00765661 ↗ “Tacrolimus (Tacro)” NCT04339777 ↗ |
| Known as | TacroBell | “Single Center, Randomized, Open-label, Phase IV Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus Tablet(TacroBell) in Kidney Transplant Recipients.” NCT04102943 ↗ |
| Known as | tacrolimus (FK 506) | “tacrolimus (FK 506)” NCT01707004 ↗ |
| Known as | Tacrolimus (TAC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01713400 ↗ |
| Known as | Tacrolimus capsules（CYONSE） | “Tacrolimus capsules（CYONSE®）” NCT04048161 ↗ |
| Known as | Tacrolimus Hexal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01649427 ↗ |
| Known as | tacrolimus modified release | “The aim of the conversion is to investigate the effects of the multi-drug resistance (MDR1, gene symbol ABCB1) genotype on the trough blood levels of tacrolimus modified...” NCT03751332 ↗ |
| Known as | Tacrolimus Modified Release (MR) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00064701 ↗ |
| Known as | tacrolimus modified/prolonged release | “Other Names: * FK506E * MR4 * tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug:...” NCT01435291 ↗ |
| Known as | Tacrolimus monohydrate | “Tacrolimus monohydrate (ADOPORT®)” NCT03076151 ↗ |
| Known as | tacrolimus MR4 | “Tacrolimus with modified galenic (tacrolimus MR4; Advagraf®) once daily.” NCT03751332 ↗ |
| Known as | Tacrolimus ointment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05856994 ↗ |
| Known as | Tacrolimus Sustained-release Capsules | “Drug: Tacrolimus Sustained-release Capsules” NCT06147648 ↗1“Drug: Tacrolimus Sustained-release Capsules” NCT06183892 ↗ |
| Known as | Tacrolimus, Prograf | “Tacrolimus (Prograf®)” NCT00679042 ↗5“Tacrolimus (Prograf®)” NCT02213068 ↗ “tacrolimus (Prograf)” NCT01005706 ↗ “Tacrolimus, Prograf” NCT00302536 ↗ “Tacrolimus: PROGRAF” NCT00922129 ↗ “Tacrolimus,Prograf” NCT00302549 ↗ |
| Known as | Tacrolimus, Prograf(R) | “Tacrolimus, Prograf(R)” NCT00360685 ↗ |
| Known as | Tacrolimus/Prograf/FK506 | “Tacrolimus/Prograf®/FK506” NCT00905515 ↗ |
| Known as | TCL | “Tacrolimus (TCL) or Cyclosporine A (CsA)” NCT04705584 ↗ |
| Known as | VI-0106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07612657 ↗ |
| Known as | ◦Drug: Tacrolimus | “◦Drug: Tacrolimus” NCT01983761 ↗ |
| Action | Inhibit | “acts as a calcineurin inhibitor” NCT00117702 ↗ |
| Modality | Small molecule | “Tacrolimus is a macrolide immunosuppressant” NCT00117702 ↗ |
| Route | Intravenous | “IV beginning one day before stem cell infusion” NCT00002831 ↗ |
| Target | IL2 | “inhibiting the expression of cytokine genes, such as IL-2” NCT00317681 ↗ |